ClinicalTrials.gg
RecruitingNCT07020247Updated Jun 13, 2025

Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study

A Phase 3 interventional study of Anti-PD-1 antibody drug named Serplulimab and Radiotherapy in Locally Advanced Rectal Cancer (LARC), Immunotherapy and Radiotherapy, sponsored by West China Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-13.

Sponsored by West China Hospital · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Nov 2024, registered Apr 2025).
  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
184
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Rectal Neoplasms by West China Hospital — 5 open to participants now, 6 under way, 3 of them phase 3. Rectal Neoplasms · West China Hospital.

Planned enrollment
5th of 12
184 · median 101
Started
2024
with 1 other
Phase 3
4 of 14
2 open now
Registered
11th of 14
by date

Among the 14 studies in Rectal Neoplasms by West China Hospital, this one is the 5th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2024, is one of 4 in phase 3, and was the 11th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

5 of the 14 studies in Rectal Neoplasms by West China Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Rectal Neoplasms by West China Hospital, or all of them as a file.
02

Study summary

The study is a multicenter, randomized controlled, phase III clinical study, and the purpose of the study is to explore the complete response rate (CR, Defined as pathological complete response (pCR) + Clinical complete response (cCR) sustained for over one year) of patients with locally advanced rectal cancer(LARC) treated with personalized long-course radiotherapy plus chemotherapy with or without Serplulimab. A total of 184 patients were included in this study.

Read the detailed description

Patients diagnosed with locally advanced rectal cancer (T3-4/N+) and presenting with combined risk factors, where the lower boundary of the lesion is ≤ 10 cm from the anal margin, will undergo neoadjuvant therapy. The primary endpoint of the study is the complete response rate (CR), defined as the combination of pathological complete response (pCR) and clinical complete response (cCR) sustained for over one year.

03

Conditions studied

  • Locally Advanced Rectal Cancer (LARC)
  • Immunotherapy
  • Radiotherapy
  • Total Neoadjuvant Therapy
  • Anal Function Preservation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: ≥18 years old; sex is not limited.
  2. Patients with stage II/III rectal cancer staged under MRI or endoscopic ultrasonography and have at least one risk factor: cT4a and invasion of intestinal lumen for more than 1/2 week (measured by MRI);cT4b(resectable);cT3c-d with EMVI+ (upper middle rectum);cN2;MRF+ (≤2mm);lower rectal cancer is located on the anterior wall and tumor reaching T3 and occupying the intestinal cavity for more than 1/2 week; lower rectal cancer is mainly located on the lateral posterior wall need invading the intestinal wall (anal sphincter) ≥ 5mm; tumor of lower rectal cancer invades the external anal sphincter or levator ani muscle (stage 4) . [According to the 8th edition of the 2018 AJCC Cancer Staging Manual and the 2008 ESMO Lower Segment Colorectal Cancer Staging Criteria] . The preoperative T stage is referred to endoscopic ultrasonography or rectal MRI. The N stage is referred to abdominal CT. The M stage is referred to abdominal and thoracic CT. If symptoms occur, other appropriate imaging examinations are needed (cranial MRI or ECT) . Patients with to MRI can be interpreted with caution based on CT and endoluminal ultrasound staging. MDT should review the staging of all patients.
  3. The lower edge of lesion is less than 10cm from anal verge according to rigid sigmoidoscopy or rectal digital examination.
  4. No distant after a thorough examination .
  5. Pathological diagnosis of rectal adenocarcinoma,and Immunohistochemistry and/or genetic testing for MSS/pMMR;
  6. score: 0-1.
  7. Patients with primary rectal cancer who had not received surgery prior to surgery (except for palliative ileostomy or colostomy), radiotherapy, systemic chemotherapy or other anti-tumor therapy.
  8. The main organ function is normal, including the following characteristics:

    ①Blood routine examination: HB ≥9g/dL, WBC ≥ 3.5/4.0×109/L,NE≥ 1.5×109/L,≥ 100×109/L

    ②Biochemical examination:Crea and BIL ≤ 1.0 upper normal limit(), and AST≤ 2.5 upper normal limit(ULN), ALP≤2.5×UNL,Tbil≤1.5×UNL。

  9. Not allergic to 5-Fu or Platinum.
  10. The site of radiotherapy had not previously received radiation.
  11. If female and of , have a negative result on a pregnancy test performed a maximum of 7 days before initiation of study treatment. If female and of childbearing potential, or if male, agree to use adequate (eg, abstinence, intrauterine device, oral contraceptive, or double-barrier method) based on the judgment of the investigator or a designated associate from the date on which the ICF ( Form) is signed until 8 weeks after the last dose of study drug.
  12. Participants are volunteered to participate in this study, sign informed consent, good compliance, cooperation with follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have previously received pelvic radiotherapy.
  2. Presence of active or progressive infection requiring systemic treatment, such as active tuberculosis, active hepatitis, etc.
  3. Presence of systemic diseases that are not stably controlled by the investigator, including diabetes mellitus, hypertension, liver cirrhosis, rheumatic immune diseases, and severe lung diseases.
  4. Have had prior or concurrent cancer distinct in primary site or histology (including synchronous colon cancer) , except for curatively treated cervical cancer in situ, Basal cell carcinoma of skin.
  5. Has any other disease, metabolic abnormality, physical examination abnormality, or laboratory abnormality that, in the judgment of the investigator, has reason to suspect that the patient has a disease or condition for which the study drug is inappropriate for use, or that would affect the interpretation of the study results, or place the patient in a high-risk condition.
  6. Estimated inadequate patient compliance to participate in this clinical study.
  7. History of gastrointestinal fistula, perforation, bleeding or severe ulceration or presence of severe gastrointestinal disease that affects the absorption of oral chemotherapy drugs.
  8. Patients who have received solid organ transplantation or bone marrow transplantation, or have had active disease requiring systemic therapy within 2 years prior to the first dose.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
184 participants (estimated)

Study arms

  • Experimental
    Total Neoadjuvant Chemoradiotherapy+Serplulimab

    The experimental group intervention consists of the following: 1. Induction Phase: Two cycles of CAPOX and serplulimab prior to radiotherapy. 2. Concurrent Chemoradiotherapy: Two cycles of CAPOX and serplulimab administered concurrently with radiotherapy. 3. Consolidation Phase: Two additional cycles of CAPOX and serplulimab, initiated 2-3 weeks after completing radiotherapy. Radiotherapy is delivered using intensity-modulated radiotherapy (IMRT/VMAT) at a dose of 50-50.4Gy/25-28f (1.8-2.0Gy/d, 5f/w). For patients in the experimental group who achieve partial remission (PR) or better during the induction phase, an additional local boost dose of 6Gy/3f (2.0Gy/d, 5f/w) is administered to the PGTV. Tumor response is assessed 3-4 weeks after completing consolidation chemotherapy. Based on the evaluation, a decision is made to proceed with either total mesorectal excision (TME) or a watchful waiting strategy.

    Drug: Anti-PD-1 antibody drug named Serplulimab · Radiation: Radiotherapy · Drug: Chemotherapy

  • Active comparator
    Total Neoadjuvant Chemoradiotherapy

    The control group intervention consists of the following: 1. Induction Phase: Two cycles of CAPOX prior to radiotherapy. 2. Concurrent Chemoradiotherapy: Two cycles of CAPOX administered concurrently with radiotherapy. 3. Consolidation Phase: Two additional cycles of CAPOX, initiated 2-3 weeks after completing radiotherapy. Radiotherapy is delivered using intensity-modulated radiotherapy (IMRT/VMAT) at a dose of 50-50.4Gy/25-28f (1.8-2.0Gy/d, 5f/w). Tumor response is assessed 3-4 weeks after completing consolidation chemotherapy. Based on the evaluation, a decision is made to proceed with either total mesorectal excision (TME) or a watchful waiting strategy.

    Radiation: Radiotherapy · Drug: Chemotherapy

Interventions

  • DrugAnti-PD-1 antibody drug named Serplulimab

    Serplulimab

  • RadiationRadiotherapy

    Radiotherapy is delivered using intensity-modulated radiotherapy (IMRT/VMAT) at a dose of 50-50.4Gy/ 25-28f(1.8-2.0Gy/d, 5f/w). For patients in the experimental group who achieve partial remission (PR) or better during the induction phase, an additional local boost dose of 6Gy/3f(2.0Gy/d, 5f/w) is administered to the PGTV.(No PGTV dose was given in the control group). For the treatment of lymph node metastasis in the lateral pelvic wall outside the mesorectal area: no additional dose is required when surgery is feasible, a sequential boost dose of 15Gy/3f is added when the lymph nodes are not surgically resectable.

  • DrugChemotherapy

    Capox

06

What researchers measure

Primary outcomes

  1. Complete response rate

    Defined as the combination of pathological complete response (pCR) and clinical complete response (cCR) sustained for over one year.

    Time frame: 1 year

Secondary outcomes

  1. R0 resection rates

    The proportion of patients achieved a complete resection with negative margin

    Time frame: 1 year

  2. Disease free survival

    Time from the completion of the treatment to any recurrences or distant metastases

    Time frame: 3 years

  3. Anus-preserving rate

    The rate of anal organ preservation patients to all patients

    Time frame: 1 year

  4. Locoregional recurrence-free survival (LRFS) rates

    The rate of patients without local recurrence to all the patients

    Time frame: 3 years

  5. Distant metastasis free survival

    Time from the completion of the treatment to any distant metastases

    Time frame: 3 years

  6. Overall survival

    OS is defined as the difference between the date of study enrollment to the date death due to any cause

    Time frame: 3 years

  7. The adverse effects during the chemoradiotherapy

    Any side effects during the chemoradiotherapy

    Time frame: 3 months

  8. Quality of life (QoL)

    Assessed using the Chinese version of QLQ-C30 to measure quality of life

    Time frame: 1 year

  9. Surgical Safety Metrics

    Surgical safety was assessed using the Clavien-Dindo classification system

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jul 2027, 32 months after the start.

Of 73 non-industry phase 3 interventional studies under Rectal Neoplasms, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 104. This study's planned 32 months is below that.

Counting every sponsor, half of 81 studies reached it within 59 months; a quarter within 37 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2025
First posted
Jun 13, 2025
StartActual
Nov 19, 2024
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jan 31, 2028
Last update
Jun 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07020247
Responsible party
Wang Xin (Professor, West China Hospital) — Principal investigator
First posted
Jun 13, 2025
Start date
Nov 19, 2024
Primary completion
Jul 31, 2027 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Jun 13, 2025

Study contacts

Wang Xin
Contact
wangxin213@sina.com
+86 28 85423609

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion